360 Health-related quality of life in patients with FRα positive platinum-resistant ovarian cancer treated with mirvetuximab soravtansine vs. investigator’s choice chemotherapy: analysis from the phase 3 MIRASOL trial
Garcia Y, Gorp T, Konecny G, Leary A, Santin A, Crusz S, Mantia-Smaldone G, Lorusso D, Colombo N, Thomes-Pepin J, Roszak A, Ottevanger P, Beiner M, Cibula D, Leath C, Li L, Method M, Moore K. 360 Health-related quality of life in patients with FRα positive platinum-resistant ovarian cancer treated with mirvetuximab soravtansine vs. investigator’s choice chemotherapy: analysis from the phase 3 MIRASOL trial. 2024, a34-a35. DOI: 10.1136/ijgc-2024-esgo.43.Peer-Reviewed Original Research